Research and Markets : Parkinsons Disease Drug Revenues Grew 17% Across Seven Major Markets, Driven by Increasingly Important Role of Dopamine Agonist Class
Tuesday February 8, 9:10 am ET
DUBLIN, Ireland--(BUSINESS WIRE)--Feb. 8, 2005--Research and Markets (http://www.researchandmarkets.com/reports/c12599) has announced the addition of Commercial Insight: Parkinsons Disease - Increased Focus on Earlier Treatment and Managing Levodopa Complications Will Drive Market Growth to their offering
Despite the growth of generic levodopa products, Parkinsons disease drug revenues grew an impressive 17% across the seven major markets to reach $1.7 billion in 2003, driven by the increasingly important role of the dopamine agonist class.
Growing evidence for the role of the dopamine agonists as first-line therapy has ensured strong growth of this class, which now account for over half of the global market. However, with several generic dopamine agonists and novel drugs expected to launch over the next decade, current players must focus on new strategies, including reformulations.
With a growth rate of 33.5% between 2002-03, the catechol-O-methyltransferase inhibitor class has witnessed the greatest year-on-year revenue growth, driven by Novartiss Comtan and the company's ability to position the drug as a treatment for niche patient cohorts. The recent launch of Stalevo will ensure the continued strong growth of this class.
Marketed therapies work primarily to treat the symptoms of Parkinsons disease. However, several compounds in development have demonstrated neuroprotective properties and have the potential to revolutionize the market. Nevertheless, reaching the market and providing convincing clinical evidence of this remains a huge challenge. However, several patent expiries and product launches are set to send the market through a period of change.
(snip)
biz.yahoo.com |
